The mTOR complex controls HIV Latency

Emilie Besnard; Shweta Hakre; Martin Kampmann; Hyung W. Lim; Nina N. Hosmane; Alyssa Martin; Michael C. Bassik; Erik Verschueren; Emilie Battivelli; Jonathan Chan; J Peter Svensson; Andrea Gramatica; Ryan J. Conrad; Melanie Ott; Warner C. Greene; Nevan J. Krogan; Robert F. Siliciano; Jonathan S. Weissman; Eric Verdin

doi:10.1016/j.chom.2016.11.001

Figure 6

An external file that holds a picture, illustration, etc.
Object name is nihms834073f6.jpg

mTOR Inhibition Causes Suppression of Reactivation of Latently Infected Cells in the Patient Model

(A) pp242- and Torin1-treated CD4 T cells in three HIV-infected patients on anti-retroviral therapy with undetectable viral load led to a drastic decrease in fold change of HIV mRNA. (B) Patient samples in (A) were regraphed to show the percentage reactivation of HIV mRNA. Significant p-values with t-test (two-sample unequal variances) are shown (**: p<0.01)